scholarly journals General principles of uncomplicated cystitis therapy during pregnancy

2021 ◽  
pp. 121-126
Author(s):  
V. L. Tyutyunnik ◽  
N. E. Kan ◽  
L. V. Khachatryan
Keyword(s):  
Pregnant Women ◽  
Clinical Symptoms ◽  
Acute Cystitis ◽  
Microbiological Test ◽  
Fosfomycin Trometamol ◽  
Acute Uncomplicated Cystitis ◽  
Tract Infections ◽  
Uncomplicated Cystitis ◽  
Total Elimination

Urinary tract infections during pregnancy are associated with severe complications. Earlier initiation of antibiotic treatment for acute uncomplicated cystitis, reduces the various complications.Objective. To assess the effectiveness of fosfomycin in the treatment of acute uncomplicated cystitis during II and III trimester of pregnancy.Material and methods. The study included 74 pregnant women who had acute uncomplicated cystitis in II or III trimesters. All patients received fosfomycin trometamol 3.754 g (equivalent to 3 g fosfomycin) as antimicrobial therapy for acute uncomplicated cystitis. The drug was prescribed to 24 pregnant women in the II, and 50 in the III trimester of pregnancy.Results. After treatment with fosfomycin signs of acute cystitis gone in all patients. At the same time, regression of clinical symptoms was noted during the next days after therapy in 95.9% (n = 71) of cases. Repeated microbiological test of the middle portion of urine was performed 7 days after the end of antibiotic therapy. In 94.6% (n = 70) cases, total elimination of the pathogen was achieved. In 5.4% (n = 4) cases, there was a significant decrease of colonization Follow-up for three months showed the absence of recurrence of acute cystitis in all pregnant women who were included in the study.Conclusion. Fosfomycin is a highly effective drug in the treatment of uncomplicated cystitis during pregnancy.

scholarly journals War and Peace: the difficult treatment of urinary tract infections and fosfomycin trometamol

2021 ◽  
Vol 23 (1) ◽  
pp. 44-53
Author(s):  
Ivan S. Palagin ◽  
Tamara S. Perepanova ◽  
D.Yu. Pushkar ◽  
Roman S. Kozlov
Keyword(s):  
Resistant Bacteria ◽  
War And Peace ◽  
Antibiotic Resistant ◽  
Global Trends ◽  
Fosfomycin Trometamol ◽  
Acute Uncomplicated Cystitis ◽  
Tract Infections ◽  
Uncomplicated Cystitis ◽  
Threat To Life ◽  
Line Drug

The title of this review “War and peace” is not accidental and the analogies with a well-known literary masterpiece have absolutely justified ground. As in the case of Lev Tolstoy’s novel this title has a profound philosophical meaning, although at first glance it may seem quite obvious. The word «war» may well correspond to those hostile changes of microorganisms leading to the current problem of antimicrobial resistance recognized worldwide. This is the “war” we have to wage against the antibiotic-resistant bacteria today. And the «peace» in this context is considered as the world, the entire universe, all people, the whole society and its reaction to what is happening. On the other hand, the word «peace» means something opposite in meaning to the word «war». Thus, the essence of the title bears a sharp contrast between military actions and peacetime, between something that carries a threat to life and peace, or illness and recovery. Preserving original novel’s structure the authors of this review consistently consider justification of fosfomycin trometamol as a first-line drug in the treatment of acute uncomplicated cystitis in women taking into account the latest research, publications and global trends.

A New Citrated Formulation of Nalidixic Acid (Mictral® U.K.) for the Treatment of Acute Cystitis

1981 ◽  
Vol 9 (3) ◽  
pp. 177-180 ◽  
Author(s):  
C Dulake ◽  
G Adam ◽  
F Allenby ◽  
A R Anderson ◽  
A Clark-Jones ◽  
...  
Keyword(s):  
Side Effects ◽  
Nalidixic Acid ◽  
Acute Cystitis ◽  
Gram Negative ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis

A 3-day course of a new citrated formulation of nalidixic acid (Mictral) was assessed in fifty-four women presenting with acute uncomplicated cystitis. Over 96% of women with a significant Gram-negative bacteriuria were cured of the infection following a course of treatment. Only two relapses occurred in this group during the follow-up period. Relief of symptoms occurred in nearly 90% of infected patients and generally by the second day of treatment. Although the incidence of side-effects was about 20% they were not considered serious.

scholarly journals Greek Version of the Acute Cystitis Symptom Score. Part I: Linguistic Validation

2020 ◽  
Author(s):  
Konstantinos Stamatiou ◽  
Evangelia Samara ◽  
Jakhongir F. Alidjanov ◽  
Kurt G. Naber ◽  
Adrian Pilatz ◽  
...  
Keyword(s):  
Symptom Score ◽  
Healthcare Professionals ◽  
American English ◽  
Greek Version ◽  
Linguistic Validation ◽  
Acute Cystitis ◽  
Original Language ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis ◽  
Self Reporting Questionnaire

Objective: The Acute Cystitis Symptom Score (ACSS) was developed and validated as a self-reporting questionnaire for diagnosing and monitoring acute, uncomplicated cystitis (AC) in female patients. The study aims at the translation of the ACSS into Greek from original Russian as a source and American English as a new master version and at its linguistic validation. Material and Methods: Three independent professional native Greek translators, two of them experts in Russian and one in English, translated the ACSS from Russian and American English into Greek. The second group of three translators translated each of the three versions back into the original language to detect or correct any important discrepancies. These three Greek versions were then used for linguistic validation. Results: The English to Greek translation reflected more the spoken language, the two Russian to Greek translations more the written, formal language. A total of 60 randomly selected females and 30 healthcare professionals was asked about their preferences and to comment on each of the three translations. Considering all comments the scientific committee (SC) developed the Greek consensus version. For cognitive assessment additional 30 healthcare professionals and 30 females were asked to comment on the intelligibility of all items. Considering their comments the linguistically validated Greek study version was established by the SC. Conclusion: The linguistically validated Greek version of the ACSS can now be used for the clinical validation study.

scholarly journals Comparative analysis of safety and efficacy of cefotaxime/sulbactam verses piperacillin/tazobactam combinations in the treatment of complicated urinary tract infections

2019 ◽  
Vol 8 (3) ◽  
pp. 512
Author(s):  
Sohil P. Makwana ◽  
Manish N. Solanki
Keyword(s):  
Urinary Tract ◽  
Clinical Symptoms ◽  
Microbiological Analysis ◽  
Cure Rate ◽  
Clinical Assessments ◽  
Clinical Scores ◽  
Significant Difference ◽  
Tract Infections ◽  
Microbiological Cure

Background: Complicated UTIs (cUTIs) are leading causes of the gram negative bacteraemia. The objective of this study was to compare efficacy and safety Cefotaxime/ Sulbactam (CTS) and Piperacillin/ Tazobactam (PT) combinations in complicated Urinary Tract Infections.Methods: Total 80 patients admitted in the hospital due to cUTI were enrolled. 31 patients were given CTS while 49 patients were given PT. Clinical symptoms were registered and scored as mild (1) moderate (2) or severe (3). The follow-up of were done daily till the patient is discharged. Thereafter, one follow up visit was done within 4 to 9 days of after discharge, termed as test of cure (TOC), and, one late follow up visit after 6 to 8 weeks was done, known as late follow up visit (LFU). Clinical assessments and microbiological analysis were done at the time of TOC and LFU.Results: At TOC visit, in CTS and PT groups, clinical scores were 1.25±3.47 and 0.86±2.35, respectively (p<0.005). Rate of clinical improvement at TOC visit was 92.00% and 92.68% while microbiological clearance was 84.00% and 87.80% with CTS and PT groups respectively. At LFU visit, clinical scores CTS and PT in groups were 1.30±3.56 and 1.32±3.37, respectively, suggesting significant improvement from baseline (p<0.005). Clinical cure rate at LFU visit was 88.00% and 87.80% while microbiological cure rate at LFU visit was 76.00% and 82.91% in CTS and PT groups respectively.Conclusions: Results suggest that both regimens have no significant difference for the treatment of cUTI. CTS and PT both are equally efficacious in treatment of cUTI.

scholarly journals Validation of the American English Acute Cystitis Symptom Score

Antibiotics ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 929
Author(s):  
Jakhongir F. Alidjanov ◽  
Kurt G. Naber ◽  
Adrian Pilatz ◽  
Florian M. Wagenlehner
Keyword(s):  
Symptom Score ◽  
Clinical Success ◽  
American English ◽  
Clinical Success Rate ◽  
Acute Cystitis ◽  
Sum Score ◽  
Patient Reported ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis ◽  
Self Reporting Questionnaire

The diagnosis of acute uncomplicated cystitis (UC) is usually based on clinical symptoms. The study aims to develop and validate the American-English Acute Cystitis Symptom Score (ACSS), a self-reporting questionnaire for diagnosis and patient-reported outcome in women with acute uncomplicated cystitis (UC). After certified translation into American-English and cognitive assessment, the clinical validation of the ACSS was performed embedded in a US phase-II trial. 167 female patients with typical symptoms of UC were included in the study following US Food and Drug Administration (FDA) guidance. At Day 1 (diagnosis), the mean (SD) sum score of the six ACSS typical symptoms reached 10.60 (2.51). Of 100 patients followed-up last time on Day 5 or 6 (End-of-treatment, EoT), 91 patients showed clinical success according to the favored ACSS criteria (sum score of typical symptoms 0.98 (1.94)). There was no correlation between the severity of symptoms on Day 1 or between clinical success rate at EoT and level of bacteriuria on Day 1. The American-English ACSS showed high predictive ability and responsiveness and excellent levels of reliability and validity. It can now be recommended as the new master version in clinical and epidemiological studies, in clinical practice, or for self-diagnosis of women with symptoms of UC.

Associated Risk Factors for Bacterial Urinary Tract Infection among Internally Displaced Pregnant Women in Niger Delta Camps, Nigeria

2021 ◽  
Vol 8 (03) ◽  
pp. 5275-5281
Author(s):  
Faith Diorgu ◽  
Maynard Ehianu ◽  
Anacletus Francis
Keyword(s):  
Risk Factors ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Pregnant Women ◽  
Niger Delta ◽  
Clinical Symptoms ◽  
Internally Displaced ◽  
Associated Risk Factors ◽  
Tract Infections

Associated Risk Factors for Bacterial Urinary Tract Infection among Internally Displaced Pregnant Women in Niger Delta Camps, Nigeria   Abstract This study investigated associated risk factors for bacterial urinary tract infection among internally displaced pregnant women in Niger Delta camps. The objectives of the study were to determine the association between age, parity, trimester of pregnancy, religion and the incidence of bacterial urinary tract infection among internally displaced pregnant women. The population of the study comprised 108 internally displaced pregnant women who also formed the study sample as no sampling method was adopted due to the limited number of study participants. The tools for data collection was midstream urine samples collected using sterile screw-capped universal containers, the instruments used in isolating the bacterial uropathogens, include Cysteine-Lactose Deficient (CLED) agar, MacConkey and Nutrient agar plates as well as a structured checklist in socio-demographic characteristics of the pregnant women. Descriptive statistics of frequency and percentage were used for data analysis and the Statistical Package for Social Sciences (SPSS) software was employed in the analytical process. Results from the study showed there was no significant association between age, parity, trimester of pregnancy, and the incidence of bacterial urinary tract infection among internally displaced pregnant women (P>0.05). However, religion was significantly associated with the incidence of bacterial urinary tract infection among internally displaced pregnant women (P<0.05).  The study concluded that there is an increasing incidence of bacterial urinary tract infections among internally displaced pregnant women linked to religious beliefs.  Based on the study findings, early routine screening of all internally pregnant women presenting or not presenting with clinical symptoms of urinary tract infection is recommended. The need for good personal and environmental hygiene to be encouraged in internally displaced persons’ camps. Keywords: Associated risk factors, Bacterial urinary tract infection, Internally Displaced Women, Camps, Niger Delta    

scholarly journals Chronic Urinary Retention due to Fowler's Syndrome

2018 ◽  
Vol 06 (01) ◽  
pp. e77-e80
Author(s):  
Jan Trachta ◽  
Johann Wachter ◽  
Jan Kriz
Keyword(s):  
Urinary Retention ◽  
Clinical Symptoms ◽  
Clean Intermittent Catheterization ◽  
Urethral Pressure ◽  
Polycystic Ovaries ◽  
Acute Cystitis ◽  
Teenage Girls ◽  
Chronic Urinary Retention ◽  
Tract Infections ◽  
Fowler’S Syndrome

AbstractFowler's syndrome (FS) is a rare cause of chronic urinary retention in teenage girls and young women. We present a case of a 14-year-old girl who presented at our hospital 2 weeks after uncomplicated laparoscopic appendectomy. The girl complained of reduced urinary frequency and prolonged micturition time. Following an acute cystitis 2 months later, she completely lost her ability to void. A comprehensive set of investigations to assess the cause of her urinary retention including a cerebral and spinal magnetic resonance imaging (MRI), and videourodynamics were performed. The diagnostic workup revealed polycystic ovaries and an asensitive and hypotonic bladder with capacity up to 1200 mL and high maximum urethral pressure of 120 cm of water. She did not tolerate clean intermittent catheterization; therefore, a suprapubic catheter was placed. Under this treatment, she suffered recurrent urinary tract infections. Two years later, she was diagnosed with FS on the basis of the medical history, clinical symptoms, and urodynamic findings. Finally, the implantation of a S3 neurostimulator restored her ability to void.

Single-Dose Treatment of Acute Cystitis with Fosfomycin Tromethamine

1998 ◽  
Vol 32 (2) ◽  
pp. 215-219 ◽  
Author(s):  
Gary E Stein
Keyword(s):  
Single Dose ◽  
Day Treatment ◽  
Acute Cystitis ◽  
Treatment Regimens ◽  
Randomized Controlled Studies ◽  
Study Selection ◽  
Fosfomycin Trometamol ◽  
Infections Urinaires ◽  
Revue De Littérature ◽  
Tract Infections

OBJECTIVE: To review the clinical pharmacology of fosfomycin tromethamine, a new antimicrobial agent for the treatment of uncomplicated lower urinary tract infections (UTIs). DATA SOURCE: Publications in English on fosfomycin, fosfomycin tromethamine, and fosfomycin trometamol (MEDLINE, 1970–1997), as well as unpublished studies submitted to the Food and Drug Administration (FDA), were reviewed. STUDY SELECTION: Comparative, randomized, controlled studies were used to analyze the efficacy and safety of fosfomycin tromethamine. DATA SYNTHESIS: Fosfomycin tromethamine is an oral antimicrobial indicated for the treatment of uncomplicated lower UTIs. This agent is active in the urine against common uropathogens that are associated with cystitis in women, including organisms resistant to other antibiotics. A single dose of fosfomycin tromethamine is well absorbed and produces therapeutic concentrations in the urine for 2–4 days. Comparative clinical trials suggest that a single dose of fosfomycin tromethamine 3.0 g is as clinically effective as 7- to 10-day treatment regimens of standard agents used to treat UTIs, such as nitrofurantoin, norfloxacin, and trimethoprim/sulfamethoxazole. Fosfomycin tromethamine is well tolerated and appears safe to use during pregnancy. CONCLUSIONS: Fosfomycin tromethamine is the only antimicrobial to be approved by the FDA for single-dose therapy in women with acute cystitis. It is as effective and safe as multidose comparators and appears safe to use during pregnancy. The acquisition cost of this new drug will need to be weighed against the improved compliance and convenience associated with its use in the treatment of uncomplicated UTIs. OBJETIVO: Revisar la farmacología de la fosfomicina trometamina, un agente antimicrobiano nuevo indicado para el tratamiento de las infecciones leves del tracto urinario. FUENTES DE INFORMACIÓN: Publicaciones en inglés sobre la fosfomicina, fosfomicina trometamina, y fosfomicina trometamol identificadas a través de MEDLINE. Además, estudios sin publicar suministrados a la Administración de Drogas y Alimentos de los Estados Unidos. SELECCIÓN DE FUENTES DE INFORMACIÓN: Estudios comparativos, controlados, y de asignación aleatoria del tratamiento de prueba, empleados para analizar la eficacia, y la seguridad de la fosfomicina trometamina. SÍNTESIS: La fosfomicina trometamina es un agente antimicrobiano oral indicado para el tratamiento de las infecciones leves del tracto urinario. Este agente es activo en la orina contra uropatógenos que están asociados con la cistitis en la mujer, incluyendo organismos resistentes a otros antibióticos. Una dosis linica de la fosfomicina trometamina se absorbe bién y produce concentracions terapéuticas en la orina for un período de 2–4 días. Estudios clínicos comparativos sugieren que una dosis única de 3.0 g de fosfomicina trometamina es tan efectiva clínicamente como un régimen de tratamiento de 7–10 días con agentes comúnmente usados en esta condición tales como la nitrofurantoína, la norfloxacina, y el sulfametoxazol con trimetoprim. La fosfomicina trometamina se tolera bién y no parecer ocasionar efectos adversos durante el embarazo. CONCLUSIONES: La fosfomicina trometamina es el único agente antimicrobiano a ser aprobado por la Administración de Drogas y Alimentos de los Estados Unidos como terapia de dosis única en mujeres con cistitis aguda. Este agente es tan efectivo y seguro como los agentes competidores usados en dosis múltiples. Además, su uso durante el embarazo parece seguro. El costo elevado de adquisición de este nuevo medicamento debe pesarse contra sus ventajas sobretodo en lo referente la mejoramiento del cumplimiento del tratamiento y conveniencia de administración en pacientes con infecciones leves del tracto urinario. OBJECTIF: Revoir la pharmacologie clinique du trométhamine de fosfomycine, un nouvel agent antimicrobien pour le traitement des infections urinaires basses non compliquées. REVUE DE LITTÉRATURE: Les publications en langue anglaise sur la fosfomycine, le trométhamine de fosfomycine, et le trométamol de fosfomycine ont été recherchées dans la banque informatisée MEDLINE aussi bien que les études non publiées soumises à l'Administration des Drogues et Alimentaires (ADA). SÉLECTION DES ÉTUDES: Les études comparatives, randomisées, et contrôlées ont été retenues pour analyser l'efficacité et l'innocuité du trométhamine de fosfomycine. RÉSUMÉ: Le trométhamine de fosfomycine est un antibiotique oral indiqué pour le traitement des infections urinaires basses non compliquées. Cet agent est actif dans l'urine contre les pathogènes du tractus urinaire responsables de la cystite chez la femme, incluant des organismes résistants à d'autres antibiotiques. Une dose unique de trométhamine de fosfomycine est bien absorbée et produit des concentrations thérapeutiques dans l'urine pour une période de 2–4 jours. Des essais cliniques comparatifs suggèrent qu'une dose unique de 3 g de trométhamine de fosfomycine est aussi efficace cliniquement qu'un traitement standard de 7–10 jours avec les agents habituellement utilisés pour le traitement des infections urinaires basses, comme la nitrofurantoïne, la norfloxacine, et le triméthoprime-sulfaméthoxazole. Le trométhamine de fosfomycine est bien toléré et semble sécuritaire lors de grossesse. CONCLUSIONS: Le trométhamine de fosfomycine est le seul antibiotique approuvé par la ADA pour la thérapie unidose de la cystite aiguë chez la femme. Il est aussi efficace et sécuritaire que les agents comparateurs à doses multiples et semble sécuritaire lors de grossesse. Le coût d'acquisition de ce nouveau médicament peut se justifier par une meilleur observance du traitement et la facilité associée à son emploi lors de traitement des infections urinaires basses non compliquées.

Sign in / Sign up

Export Citation Format

Share Document